Elevance Health's results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-21. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $51,429 million (+1.4% vs a year earlier) |
| Diluted EPS (GAAP) | $6.27 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $6.99 |
| Full-year guidance | Raised |
Guidance
Elevance Health raised FY2026 guidance: diluted EPS at least $22.00, adjusted diluted EPS at least $29.00, operating cash flow at least $6.5 billion.
Why this label: Headline 'RAISES FULL-YEAR GUIDANCE': FY2026 diluted EPS raised to at least $22.00, adjusted EPS to at least $29.00.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| diluted EPS | FY2026 | at least $22.00 | not stated |
| adjusted diluted EPS | FY2026 | at least $29.00 | not stated |
| operating cash flow | FY2026 | at least $6.5 billion | not stated |
From the release
Revenue: "Total revenues · 51,429 · 50,711 · 1.4%"
Earnings per share: "3Q 2026 diluted EPS 1 of $6.27 and adjusted diluted EPS 2 of $6.99"
diluted EPS: "FY 2026 diluted EPS 1 guidance raised to at least $22.00"
adjusted diluted EPS: "adjusted diluted EPS 2 guidance raised to at least $29.00 on continued operating momentum"
operating cash flow: "FY 2026 operating cash flow guidance raised to at least $6.5 billion"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Raised FY2026 adjusted diluted EPS guidance to at least $29.00
Source
Elevance Health earnings release (SEC filing), accession 0001156039-26-000068, filed 2026-10-21.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.